Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.06 and traded as high as $0.06. Mateon Therapeutics shares last traded at $0.06, with a volume of 363,734 shares.
Mateon Therapeutics Trading Down 2.3%
The firm has a market cap of $5.36 million, a P/E ratio of -2.97 and a beta of 1.33. The firm has a 50-day simple moving average of $0.04 and a 200-day simple moving average of $0.06.
About Mateon Therapeutics
Mateon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies that selectively target tumor tissue. The company’s platform leverages tumor-activated peptides designed to bind to the fibrin–fibronectin complexes uniquely present in solid tumors, with the goal of improving the therapeutic index of cytotoxic payloads while limiting off-target effects.
Its lead asset, MH1, is a peptide–drug conjugate in Phase I clinical trials for advanced solid tumors.
Recommended Stories
- Five stocks we like better than Mateon Therapeutics
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
